Indication
Measles-Rubella Immunity Deficiency
1 clinical trial
1 product
Clinical trial
A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma.Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Dostarlimab-Gxly